New pill aims to stop Chemo-Induced nausea in its tracks
NCT ID NCT06554184
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called HR20013 to see if it works better than an existing drug (palonosetron) at preventing nausea and vomiting caused by moderate-risk chemotherapy. Over 700 cancer patients who had never had chemo before took part. The main goal was to see how many patients had no vomiting and didn't need extra medication in the delayed phase (24-120 hours after chemo).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HR20013 (a drug to prevent nausea and vomiting)
What this could lead to
If it works, this could offer a new option to prevent nausea and vomiting after chemotherapy, improving comfort for cancer patients.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not be more effective than existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETIC RISK ANTICANCER AGENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center Yuexiu Campus
Guangzhou, Guangdong, 510000, China